# NCT04876651 (NCT04876651)

> The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

No report yet. It can be ordered.

- Indication: PSMA-expressing metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04876651
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd
- Conditions: Metastatic Prostate Cancer
- Interventions: 177Lu-DOTA-rosopatamb; Standard of Care
- Enrollment: 16
- Primary outcome: Comparison of radiographic progression-free survival (rPFS)

## Some of the questions raised in the 9 indexed sources

_Automated from all 9 indexed sources (Jan 2022 – Jun 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether adding 177Lu-rosopatamab to an ARPI or docetaxel improves on that standard of care alone
- Whether 177Lu-rosopatamab in ProstACT offers more than 177Lu-PSMA-617, and how the two would be sequenced
- Whether 177Lu-rosopatamab spares salivary glands and kidneys, and what its liver uptake means for safety

## Indexed commentary on NCT04876651 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 posts on X
- 2 YouTube videos
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct04876651

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04876651", "email": "<work email>"}; the inbox owner confirms by the emailed link.
